Announcement on Changing Signatory Certified Public Accountant
Filed with SSE · · 2 pages · Chinese
Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix
Earlier from Chongqing Genrix Biopharmaceutical
- Announcement on Voluntary Disclosure of the Inclusion of the Xeligekimab Injection in the 2025 National Medical Insurance Catalog
- Announcement on Resolutions of the 5th Meeting of the 2nd Board of Directors
- Announcement on Voluntary Closure of the Commercialization Cooperation for Vecantoxatug Monoclonal Antibody Injection and Silevimig Monoclonal Antibody Injection
- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Chongqing Jurisdiction and Semi-Annual Performance Briefing
- Announcement on Voluntary Disclosure on the Acceptance of Talizumab Injection
Later from Chongqing Genrix Biopharmaceutical
- Announcement on Voluntary Disclosure on the Acceptance of Conditional Listing Application for GR1803 Injection
- Announcement on Voluntary Disclosure of Inclusion GR1803 Injection in the List of Priority Review Drugs
- Announcement on Resignation of Independent Director
- Earnings Preannouncement for 2025
- Announcement on Resolutions of the 6th Meeting of the 2nd Board of Directors
Follow Chongqing Genrix Biopharmaceutical into a list and get an email when it puts out news.
Follow Chongqing Genrix Biopharmaceutical